Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab Auto-injector Device in Atopic Dermatitis
NCT03050151Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2017
- Primary completion
- Nov 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dupilumab in atopic dermatitis (AD) (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Number of validated AI device-associated product technical failures (PTFs) at 12 weeks and Type of validated AI device-associated PTFs at 12 weeks. Started Feb 2017; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03050151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03050151.